SM
FOLD

Sciencast Management’s Amicus Therapeutics FOLD Stock Holding History

Sciencast Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,624
Closed -$100K – 281
2024
Q4 		$100K Buy
+10,624
New +$110K 0.03% 239

Other funds holding FOLD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Sciencast Management's FOLD Position: Q1 2025 in Review

Sciencast Management sold out of Amicus Therapeutics (FOLD) in Q1 2025, closing a stake of 10,624 shares — an estimated $100K sold.

Sciencast Management first reported a position in FOLD in Q4 2024 and held it in 1 quarter. The position peaked at $100K in Q4 2024. 286 funds tracked by Wall St. Rank hold FOLD as of Q1 2025.

  • Sciencast Management reported no remaining Amicus Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Sciencast Management sold 10,624 Amicus Therapeutics shares in Q1 2025, an estimated $100K.
  • Sciencast Management first reported a position in Amicus Therapeutics in Q4 2024 and held it in 1 quarter.
  • Sciencast Management's Amicus Therapeutics position peaked at $100K in Q4 2024.
  • 286 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2025.

Based on Sciencast Management's 13F filing for Q1 2025, filed 16 May 2025.